Société The Carlyle Group Inc.
Actions
CG
US14316J1088
Gestion des placements et exploitants de fonds
Marché Fermé -
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
43,05 USD | -0,81 % | +1,29 % | +5,80 % |
Métier
Nombre d'employés: 2 200
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
William Conway
FOU | Founder | 74 | 01/01/87 |
David Rubenstein
FOU | Founder | 74 | 01/01/87 |
Harvey Schwartz
CEO | Chief Executive Officer | 60 | 15/02/23 |
John Redett
DFI | Director of Finance/CFO | 56 | 01/01/07 |
Lúcia Soares
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/19 |
Jason Thomas
CTO | Chief Tech/Sci/R&D Officer | - | 01/12/10 |
Ruulke Bagijn
CIO | Chief Investment Officer | - | 01/05/19 |
Christopher Finn
COO | Chief Operating Officer | 66 | 01/03/19 |
Bethany de Lude
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/21 |
Catherine Ziobro
CMP | Compliance Officer | - | 01/01/04 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
William Shaw
BRD | Director/Board Member | 78 | 02/05/12 |
Lawton Fitt
BRD | Director/Board Member | 70 | 02/05/12 |
Linda Filler
BRD | Director/Board Member | 64 | 01/04/22 |
Derica Rice
BRD | Director/Board Member | 59 | 08/03/21 |
Anthony Welters
BRD | Director/Board Member | 69 | 27/10/15 |
James Hance
BRD | Director/Board Member | 79 | 01/11/05 |
William Conway
FOU | Founder | 74 | 01/01/87 |
David Rubenstein
FOU | Founder | 74 | 01/01/87 |
Daniel D'Aniello
FOU | Founder | 77 | 01/01/87 |
Harvey Schwartz
CEO | Chief Executive Officer | 60 | 15/02/23 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 359 880 497 | 260 652 292 ( 72,43 %) | 0 | 72,43 % |
Participations
Nom | Actions | % | Valorisation |
---|---|---|---|
ADICON HOLDINGS LIMITED 38,71% | 281 541 805 | 38,71% | 420 448 901 $ |
HOKUETSU CORPORATION 0,16% | 293 449 | 0,16% | 2 500 652 $ |
SAKATA INX CORPORATION 0,41% | 221 000 | 0,41% | 2 255 431 $ |
RENGO CO., LTD. 0,08% | 209 608 | 0,08% | 1 578 403 $ |
NAGASE & CO., LTD. 0,04% | 51 000 | 0,04% | 884 597 $ |
ARTIENCE CO., LTD. 0,05% | 31 748 | 0,05% | 590 112 $ |
193 195 | 5,24% | 349 683 $ | |
49 461 | 0,04% | 346 367 $ | |
DAIO PAPER CORPORATION 0,03% | 44 227 | 0,03% | 318 426 $ |
LINTEC CORPORATION 0,01% | 5 000 | 0,01% | 100 086 $ |
Coordonnées société
The Carlyle Group, Inc.
1001 Pennsylvania Avenue NW
20004-2505, Washington
+202 729 5626
http://www.carlyle.comSociétés du groupe
Nom | Catégorie et Secteur |
---|---|
Abingworth Bioventures V LP
|
Investment Managers
|
Carlyle Investment Management LLC
Carlyle Investment Management LLC Investment ManagersFinance Carlyle Investment Management LLC provides investment advisory services. It provides retail insurance and investment services across the US. The company's life insurance products include universal life insurance, term life coverage, and variable annuities. It was founded in 2007 and is located in Washington, DC. |
Investment Managers
|
Abingworth Bioventures V Co-Invest Growth Equity Fund LP
|
Investment Managers
|
ABV 8 Strategic UK LP
|
Miscellaneous
|
Abingworth LLP
Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. |
Investment Managers
|
Abingworth Bioventures 8 LP
Abingworth Bioventures 8 LP Investment ManagersFinance Abingworth Bioventures 8 LP invests in private and public companies located across the UK, Europe and the US. The fund targets companies operating in the fields of medical devices, instrumentation, bio therapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, medical devices, diagnostics and instrumentation. It provides financing for seed, early and later-stage capital requirements with an investment size ranging from $15 million to $30 million. It also makes majority or minority investments. |
Investment Managers
|
Abingworth Bioventures VII LP
Abingworth Bioventures VII LP Investment ManagersFinance Abingworth Bioventures VII LP invests in private and public companies located in the US and Europe. The fund targets companies operating in the fields of life sciences and healthcare sectors such as medical devices, instrumentation, biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, diagnostics and software. It provides financing for seed, early and later-stage capital requirements with an investment size of $15 - $30 million. It seeks majority or minority investments in the companies. |
Investment Managers
|
Abingworth Bioventures VI LP
Abingworth Bioventures VI LP Investment ManagersFinance Abingworth Bioventures VI LP invests in private and public companies located the US and Europe. The fund targets companies operating in the fields of medical devices, instrumentation, bio therapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, diagnostics and software. The fund provides financing for seed, early and late stage capital requirements with an investment size of $15 - $30 million. It seeks Majority or minority investments in the companies. |
Investment Managers
|
AlpInvest Partners BV
AlpInvest Partners BV Investment ManagersFinance AlpInvest Partners BV (AlpInvest) is a private equity asset subsidiary AP BV, ultimately owned by The Carlyle Group, Inc founded in 2000. AlpInvest Partners BV is headquartered in Amsterdam, the Netherlands. |
Investment Managers
|
Secteur
Révisions de BNA
Chiffre d'affaires trimestriel - Taux de surprise
Varia. 1 janv. | Capi. | |
---|---|---|
+5,80 % | 15,49 Md | |
-4,01 % | 95,41 Md | |
+26,30 % | 92,86 Md | |
+22,44 % | 28,35 Md | |
+0,84 % | 19,01 Md | |
+16,40 % | 15,8 Md | |
-18,50 % | 12,77 Md | |
+18,15 % | 9,7 Md | |
+27,52 % | 9,52 Md | |
+28,76 % | 7,26 Md |